Loading stock data…
Thermo Fisher Scientific Inc (TMO)
$505.59-7.44 (-1.45%)
Market OpenUpdated 11:03 AM EDT
Thermo Fisher Scientific Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Thermo Fisher Scientific Inc. in the Healthcare sector is trading at $505.59 with a market capitalization of $165.3B. Wall Street consensus targets $596.26 (27 analysts), implying a +17.9% move over the next 12 months. The stock is currently 21% below its 52-week high of $643.99, remaining 3.7% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +17.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $11.01B↓ | $12.21B↑ | $11.12B↑ | $10.85B↑ | $10.36B |
| Gross Profit | $4.43B↓ | $5.01B↑ | $4.58B↑ | $4.41B↑ | $4.24B |
| Operating Income | $1.91B↓ | $2.30B↑ | $2.08B↑ | $1.92B↑ | $1.81B |
| Net Income | $1.65B↓ | $1.96B↑ | $1.62B | $1.62B↑ | $1.51B |
Peer Comparison
JNJUNHPFE
Fundamentals
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four se...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$165.35B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
24.45
Beta
Defensive asset. Lower volatility than the S&P 500.
0.88
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.35%
ROE
Average efficiency. Growth may require heavy reinvestment.
13.19%
Volume
Today's trading volume
414,937
Recent News
Is Danaher (DHR) One of the Best Non-Tech Stocks to Buy According to Analysts?
Danaher Corporation (NYSE:DHR) is one of the best non-tech stocks to buy according to analysts. Masimo, Danaher Corporation’s (NYSE:DHR) specialty diagnostics solutions innovator of pulse oximetry and other patient monitoring solutions, announced on June 22, FDA 510(k) clearance for an opioid-induced respiratory depression detection capability integrated into the Radius VSM® wearable continuous patient monitor. Supported […]
Bernstein Says Life Science Sector is Improving, Resumes Thermo Fisher Scientific (TMO) Coverage
Thermo Fisher Scientific Inc. (NYSE:TMO) is included among Billionaire Steven Cohen’s Top 11 Dividend Stock Picks. On June 26, Bernstein resumed coverage of Thermo Fisher Scientific Inc. (NYSE:TMO) with a Market Perform rating. It also set a $520 price target after the analyst returned from maternity leave. In a research note, the firm said “Many […]
Just How Far Could Corning Stock Swing From Here?
If you hold shares in the specialty glass and ceramics maker, you are already carrying exposure to a remarkably wide range of potential outcomes priced by the options market.
Thermo Fisher Scientific (TMO) Stock After Recent Volatility Is The Current Price Reasonable
If you are wondering whether Thermo Fisher Scientific at around US$505 per share offers good value or is pricing in too much optimism, the key is to understand what the current valuation actually reflects. The stock has seen mixed recent performance, with a 7 day return of 8.9% and a 30 day return of 12.8%, set against a year to date decline of 14.6% but a 23.2% gain over the last year. These swings in Thermo Fisher Scientific's share price sit against a backdrop of ongoing attention on...
Is Thermo Fisher (TMO) Quietly Redefining Its Edge With AI-Enabled, End-to-End Biopharma Tools?
Earlier this week, Thermo Fisher Scientific used the BIO International Convention 2026 in San Diego to showcase new Orbitrap mass spectrometry upgrades, AI-powered software, and integrated laboratory solutions aimed at supporting complex research and biopharma development workflows. The company’s decision to spotlight end-to-end, AI-enabled capabilities across pharma services and bioproduction underlines its ambition to be a single, integrated partner for drug development from discovery...